

**Annual Report**  
**on**  
**Social Security Pre-effectuation Reviews of**  
**Favorable State Disability Determinations**



**Fiscal Year 2022**

**PRE-EFFECTUATION REVIEW OF FAVORABLE  
STATE DISABILITY DETERMINATIONS BY  
THE SOCIAL SECURITY ADMINISTRATION  
FISCAL YEAR 2022**

**Background**—We submit this annual report pursuant to section 221(c)(3)(C) of the Social Security Act (Act). The Act requires us to report to the Committee on Ways and Means of the House of Representatives and to the Committee on Finance of the Senate on the pre-effectuation reviews (PER) conducted during the previous fiscal year of disability and blindness determinations<sup>1</sup> made by the State disability determination services (DDS). The legislative mandate specifies that the PER report include information on: (1) the numbers of such reviews; and (2) our findings based on such reviews of the accuracy of the State DDS determinations.

Title II of the Act requires the Commissioner to review at least 50 percent of all State DDS initial and reconsideration allowances of applications for Old-Age, Survivors, and Disability Insurance (OASDI) benefits based on disability. The Act further requires the Commissioner to review a sufficient number of OASDI medical continuing disability review (CDR) continuance determinations by State DDSs to ensure a high level of accuracy in such determinations.

In addition, Public Law 109-171, the Deficit Reduction Act of 2005, added section 1633(e) to Title XVI of the Act, requiring similar PERs of specified levels of DDS allowances of applications by persons aged 18 or older for Supplemental Security Income (SSI) benefits based on disability. Since fiscal year (FY) 2008, the required level of our SSI reviews is also at least 50 percent of initial and reconsideration allowances.

We present the PER results for FY 2022 in Table 1. The following paragraphs summarize some of the key findings.

**Initial and reconsideration allowances**—We reviewed 246,586 Title II allowances under the PER process, representing 53.0 percent of all DDS allowances for Title II disability benefits in FY 2022. We returned 12,396 deficient cases to DDS offices, representing a return rate of 5.0 percent. After corrective action, we estimate that 5,286 of these deficient initial and reconsideration allowances will change to denials, representing a change rate of 2.1 percent of the total reviews of allowances initiated under Title II.<sup>2</sup> Table 1 presents these overall results for reviews initiated under Title II, split between cases that involved only Title II benefits and those cases that also involved Title XVI benefits.

In addition, for cases involving only Title XVI disabled adults, we reviewed 73,043 initial and reconsideration allowances during FY 2022, representing 50.5 percent of all DDS allowances for adult SSI benefits. We determined that 2,698 of these cases were deficient and returned them to DDS offices for corrective action, representing a return rate of 3.7 percent. After corrective action, we estimate that 1,074 of these deficient initial and reconsideration allowances will change to denials, representing a change rate of 1.5 percent of the total reviews of Title XVI adult allowances.<sup>2</sup>

<sup>1</sup> The Act requires these reviews for determinations involving either disability or blindness. For convenience, we will refer to these collectively as “disability” or “disabled” determinations throughout this report.

<sup>2</sup> Individuals whose disability decision is reversed due to pre-effectuation review have the right to appeal such reversal. The cited numbers do not reflect the effect of any appeals activity.

It is important to note that we base both the Title II and Title XVI change rate projections on the results of corrective action on at least 95 percent of deficient PER cases; therefore, the actual number of changed decisions could vary slightly from the projected numbers.

**Disability continuance determinations**—In FY 2022, we initiated 5,662 PERs of favorable Title II CDR determinations, representing 2.7 percent of all such DDS continuances. Of these reviews, we returned 110 deficient CDR continuances to State DDS offices, representing a return rate of 1.9 percent. After deficient continuances are corrected, we estimate that 52 of the continuance determinations reviewed in FY 2022 will change to cessations, an estimated change rate of 0.9 percent. Of the 5,662 CDR continuances we reviewed, 1,084 were concurrent Title II/XVI continuances. Unlike Title II, there is no requirement to review any Title XVI-only CDR continuances, and we conducted no such reviews in FY 2022.

Table 1.—Pre-effectuation Reviews in FY 2022					
	Reviews initiated under Title II			Reviews initiated under Title XVI	Total
	Title II-only reviews	Title II reviews involving title XVI recipients	Subtotal, Title II		
<b>Universe of cases subject to PER—</b>					
DDS allowances:					
Initials .....	322,536	95,899	418,435	130,913	549,348
Reconsiderations .....	32,897	14,017	46,914	13,734	60,648
Total, initials and reconsiderations .....	355,433	109,916	465,349	144,647 <sup>a</sup>	609,996
CDR continuances .....	182,853	28,703	211,556		211,556
<b>Cases reviewed—</b>					
<i>Number of cases:</i>					
Initials .....	146,257	68,771	215,028	64,335	279,363
Reconsiderations .....	20,227	11,331	31,558	8,708	40,266
Total, initials and reconsiderations .....	166,484	80,102	246,586	73,043 <sup>a</sup>	319,629
CDR continuances .....	4,578	1,084	5,662		5,662
<i>Percent of corresponding cases subject to PER:</i>					
Initials .....	45.3%	71.7%	51.4%	49.1%	50.9%
Reconsiderations .....	61.5%	80.8%	67.3%	63.4%	66.4%
Total, initials and reconsiderations .....	46.8%	72.9%	53.0%	50.5%	52.4%
CDR continuances .....	2.5%	3.8%	2.7%	<sup>a</sup>	2.7%
<b>Cases returned for correction—</b>					
<i>Number of cases:</i>					
Initials .....	6,833	3,705	10,538	2,331	12,869
Reconsiderations .....	1,160	698	1,858	367	2,225
Total, initials and reconsiderations .....	7,993	4,403	12,396	2,698 <sup>a</sup>	15,094
CDR continuances .....	95	15	110		110
<i>Percent of corresponding cases reviewed:</i>					
Initials .....	4.7%	5.4%	4.9%	3.6%	4.6%
Reconsiderations .....	5.7%	6.2%	5.9%	4.2%	5.5%
Total, initials and reconsiderations .....	4.8%	5.5%	5.0%	3.7%	4.7%
CDR continuances .....	2.1%	1.4%	1.9%	<sup>a</sup>	1.9%
<b>Cases projected to have decision changed after review—</b>					
<i>Number of cases:</i>					
Initials .....	2,705	1,639	4,344	906	5,250
Reconsiderations .....	574	368	942	168	1,110
Total, initials and reconsiderations .....	3,279	2,007	5,286	1,074 <sup>a</sup>	6,360
CDR continuances .....	46	6	52		52
<i>Percent of corresponding cases reviewed:</i>					
Initials .....	1.8%	2.4%	2.0%	1.4%	1.9%
Reconsiderations .....	2.8%	3.2%	3.0%	1.9%	2.8%
Total, initials and reconsiderations .....	2.0%	2.5%	2.1%	1.5%	2.0%
CDR continuances .....	1.0%	0.6%	0.9%	<sup>a</sup>	0.9%
<sup>a</sup> Pre-effectuation reviews of Title XVI CDR continuances are not required, and we conducted none in FY 2022.					

<sup>a</sup> Pre-effectuation reviews of Title XVI CDR continuances are not required, and we conducted none in FY 2022.

**Findings on the accuracy of favorable disability determinations under Title II and Title XVI—**


Based on results of our PERs in FY 2022, we found that the decision to allow or continue was supportable in 97.9 percent of all DDS favorable Title II disability determinations. We found that the decision to allow was supportable in 98.5 percent of all DDS favorable Title XVI-only adult disability determinations.

**Estimated net reductions in Federal program outlays attributable to PER—**Individuals denied because of a PER, as with other DDS-level determinations, may appeal the determination. Following all appeals, we estimate that 2,907 Title II initial and reconsideration error cases (1.2 percent of all such PER reviews) will remain denials. For the corresponding reviews of Title XVI-only adult cases, we estimate that 738 cases (1.0 percent of all such PER reviews) will remain denials. For reviews of Title II CDR cases, we estimate that 26 of the continuance cases with errors (0.5 percent of all such reviews) will remain cessations after all appeals. These changed determinations result in a reduction in lifetime program outlays that would have been payable from the OASDI and SSI programs had we not conducted the PERs, along with net reductions in Medicare program outlays and a small net increase in Medicaid program outlays. Overall, we estimate that the PER process for FY 2022 will result in net reductions in Federal program outlays totaling \$975 million in net lifetime Federal benefits. We present details of these estimates in Table 2.

<b>Table 2.—Estimated Net Lifetime Federal Benefit Reductions in Program Outlays Due to the Pre-Effectuation Review of Disability Cases in Fiscal Year 2022</b>			
Item	Initial and reconsideration allowances	CDR continuances	Total, all reviews
Estimated number with decision changed after review, and after all appeals:			
Cases initiated under Title II.....	2,907	26	2,933
Cases initiated under Title XVI.....	738	<sup>a</sup>	738
Estimated present value of net lifetime program outlay reductions, as of the end of FY 2022 (in millions):			
OASDI benefit payments <sup>b</sup> .....	\$640	\$6	\$645
Medicare benefit payments <sup>c</sup> .....	276	3	279
Federal SSI payments:			
Title XVI-only cases .....	40	<sup>a</sup>	40
Concurrent cases .....	14	<sup>c</sup>	14
Subtotal, SSI payments .....	54	<sup>c</sup>	54
Federal share of Medicaid payments <sup>c, d</sup> :			
Title XVI-only cases .....	-3	<sup>a</sup>	-3
Concurrent cases .....	<sup>c</sup>	<sup>c</sup>	<sup>c</sup>
Subtotal, Medicaid payments .....	-3	<sup>c</sup>	-3
Total, all Federal program outlays:			
Cases initiated under Title II .....	930	9	938
Cases initiated under Title XVI .....	37	<sup>a</sup>	37
Total .....	967	9	975
<sup>a</sup> Pre-effectuation reviews of Title XVI CDR continuances are not required, and we conducted none in FY 2022.			
<sup>b</sup> Includes a net reduction in program outlays of \$10.8 million from changing the date of disability onset in certain initial and reconsideration cases.			
<sup>c</sup> The Office of the Actuary in the Centers for Medicare & Medicaid Services provided the estimates shown for net reductions in Medicare and Medicaid program outlays.			
<sup>d</sup> Due to the timing of when the Medicaid estimates were developed, the estimates do not reflect the effects of Public Law 119-21, the One Big Beautiful Bill Act, enacted on July 4, 2025.			
<sup>e</sup> Between -\$0.5 million and \$0.5 million.			
Notes:	<p>1. The estimates are based on the intermediate assumptions from the <i>2023 Annual Report of the Board of Trustees of the Federal Old-Age and Survivors Insurance and Federal Disability Insurance Trust Funds</i>, the intermediate assumptions of the <i>2023 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds</i>, and assumptions underlying the <i>2023 Annual Report of the Supplemental Security Income Program</i>.</p> <p>2. The estimated net program outlay reductions represent the direct effects on net lifetime Federal benefits of disability applications ultimately denied OASDI or SSI program eligibility as a result of the PER process. See the body of the report for further information.</p> <p>3. Totals may not equal sum of components due to rounding.</p>		

As shown in Table 2, we estimate that the action taken in these cases will result in net lifetime reductions in program outlays (after all appeals) of \$645 million in OASDI benefit payments, \$54 million in Federal SSI payments, \$279 million in Medicare benefits, and a net increase of \$3 million in the Federal share of Medicaid payments. The Medicaid estimates reflect the effects of an Affordable Care Act provision whereby States, starting in 2014, provide Medicaid coverage to individuals residing in households with income up to 138 percent of poverty<sup>3</sup> with significantly higher Federal matching on the benefits paid under the expanded coverage than without the expansion.<sup>4</sup> We illustrate the relative size of these contributions of program outlay reductions attributable to the PER process in the chart below. It is important to note that the estimated net program outlay reductions presented in this report represent the direct effects on net lifetime Federal benefits of disability applications ultimately denied OASDI or SSI program eligibility as a result of the PER process. In addition to the direct program outlay reductions resulting from PER in FY 2022, there is an indirect effect on determinations where adjudicators are more thorough and accurate as a result of feedback from PER in prior case determinations. Such indirect effects are not reflected in the estimates shown in Table 2 and the accompanying chart.

The direct administrative cost of performing PERs of 319,629 allowances and 5,662 continuances was about \$55 million. This amount, however, does not include the cost of processing appeals of allowances or continuances that we reversed to denials or cessations after a PER. We estimate the total amount expended to achieve these estimated Federal program outlay reductions, including the cost of processing appeals of PER reversals, to be approximately \$72 million. Thus, we estimate that the reviews conducted in FY 2022 will result in net reductions of approximately \$18 on average per \$1 spent directly on PERs, or about \$13 on average per \$1 of the total cost of PERs. We present a complete summary of these benefit-to-cost ratio results in Table 3 below.



<sup>3</sup> The Affordable Care Act provides this Medicaid expansion for households with adjusted gross income up to 133% of the Federal poverty level; however, in practice, households are provided with a 5% exclusion of adjusted gross income, effectively making the expansion available for households under 138% of Federal poverty.

<sup>4</sup> Due to the timing of when the Medicaid estimates were developed, the estimates do not reflect the effects of Public Law 119-21, the One Big Beautiful Bill Act, enacted on July 4, 2025.

<b>Table 3.—Estimated Cost Effectiveness of the FY 2022 PER Process</b>			
Item	Reviews initiated under --		Total, all reviews
	Title II	Title XVI	
Estimated present value <sup>a</sup> of net lifetime Federal program outlay reductions under the OASDI, SSI, Medicare, and Medicaid programs (in millions) .....	\$938	\$37	\$975
Cost of conducting PER (in millions):			
Direct cost of PER reviews.....	48	6	55
Estimated cost of appeals of PER reversals .....	17	1	18
Total cost of PER.....	65	7	72
Program outlays reduced per \$1 of --			
Direct PER review cost <sup>b</sup> .....	19.4	5.8	17.8
Total PER cost <sup>a</sup> .....	14.4	5.0	13.5
<sup>a</sup> As of September 30, 2022			
<sup>b</sup> Computed using unrounded amounts of estimated benefits and administrative expenses.			
Note: Totals may not equal sum of components due to rounding.			

As indicated in Table 3, reviews conducted in FY 2022 that were initiated under Title II resulted in significantly higher reductions in Federal program outlays as those initiated under Title XVI on average, per \$1 of the cost of conducting PERs.